Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
BICO Group AB is a Sweden-based bioconvergence company specializing in lab automation and life science solutions for the healthcare industry. Originally founded as CELLINK in 2015 in Gothenburg from research at Chalmers University of Technology, it pioneered 3D bioprinting with revolutionary bioinks—hydrogel-based materials enabling the printing of living human cells into 3D structures for tissue engineering, drug discovery, and regenerative medicine. Rebranded in 2021, BICO integrates biology, engineering, and digital technologies to automate life science labs, serving leading pharma and biotech firms with products like Green Button Go software for lab orchestration, off-the-shelf automation tools, bioprinting systems, and brands such as Biosero, CELLINK, and Nanoscribe. Its portfolio spans lab automation, biosciences, bioautomation, and laboratory solutions, with over 48,000 instruments deployed globally across 25+ countries and cited in 12,000+ publications. Employing more than 500 people, BICO drives efficiency by reducing manual tasks, standardizing data for AI applications, and accelerating therapy development to foster innovation in healthier societies.
kr 1.48
kr 0.00 (-0.13%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-16.42% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 13.3% YoY. Margins deteriorated 4.9pp alongside, both lines moving the wrong way.
Free cash flow declined 40% versus the prior year, cash generation momentum has weakened. ROIC dropped from -2.70% to -4.98%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 1.49B
▼ -13.3% YoY
Net Income (TTM)
-kr 989M
▼ -12045.6% YoY
Op. Margin
-17.37%
▼ -4.9pp YoY
ROIC
-4.98%
▼ -2.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
kr 15M
▼ -40.3% YoY
Op. Cash Flow (TTM)
kr 20M
▼ -55.1% YoY
Net Debt
kr 89M
Cash & Equiv.
kr 1.20B
3Y CAGR: -11.0%
Continue Research
BICO Group AB (BICO.XSTO) trades below a two-stage DCF intrinsic value of about SEK 2.49 per share, so at SEK 1.48 the stock looks undervalued (68.2% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, BICO Group AB scores 6/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about SEK 2.49 per share for BICO.XSTO, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around SEK 1.87. At today's SEK 1.48, that puts the stock about 68.2% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
BICO Group AB scores 6 out of 100 on Intrinsiqq's quality score, passing 0 of 7 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -17.4% operating margin and a -5.0% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. BICO.XSTO currently trades below its estimated intrinsic value and scores 6/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.